Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nanobiotix S.A. ADR (NQ: NBTX ) 4.160 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Nanobiotix S.A. ADR < Previous 1 2 3 4 5 Next > NANOBIOTIX to Participate in Multiple Investor Conferences in November October 31, 2024 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company October 11, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results September 18, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth September 04, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company August 08, 2024 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company July 09, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 June 12, 2024 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company June 11, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy June 02, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call May 28, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX to Present at the Jefferies Global Healthcare Conference May 23, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update May 22, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth May 21, 2024 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company May 16, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 May 15, 2024 Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer May 14, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results April 24, 2024 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 April 17, 2024 Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company April 10, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation April 02, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix to Present at Upcoming Investor Conferences in March March 06, 2024 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company February 13, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference January 31, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study January 29, 2024 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company January 11, 2024 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets December 26, 2023 From Nanobiotix S.A. Via GlobeNewswire Voting Rights and Shares Capital of the Company December 13, 2023 From Nanobiotix S.A. Via GlobeNewswire Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc. December 04, 2023 From Nanobiotix S.A. Via GlobeNewswire NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update November 13, 2023 From Nanobiotix S.A. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
